German Center for Lung Research (DZL)’s Post

Breaking the vicious cycle: Triple therapy strengthens nasal mucosal barrier function Treatment with the #CFTR modulators elexacaftor, tezacaftor and ivacaftor improves innate defenses in the nasal mucosa and reduces inflammatory reactions in children with #cystic #fibrosis. This was shown by researchers at the Charité - Universitätsmedizin Berlin in a study funded by Mukoviszidose e.V. using epithelial and immune cells from the upper respiratory tract. The #triple #therapy with the CFTR modulators elexacaftor, tezacaftor and ivacaftor for patients with cystic fibrosis (CF), which is approved in Europe since 2020, is effective and safe. This has now been confirmed in long-term studies of up to three years. It is also now known that the function of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel, which is affected by CF, recovers under treatment. Researchers at the Charité - Universitätsmedizin Berlin have now shown in single cells from the nasal mucosa of children with CF aged 6 to 11 years that the #inflammatory reactions of the immune cells in the upper #respiratory tract decrease under #triple #therapy and that the innate defenses also recover. The results underline the potential of CFTR modulators to stop the vicious cycle of infection, inflammation, and progressive lung damage in CF and to restore epithelial homeostasis and immune defense, especially if treatment is started early," said Dr. Saskia Trump, who led the study together with Dr. Simon Gräber and Prof. Marcus Mall. The epithelium is the uppermost cell layer of the mucosa and plays a crucial role in maintaining a stable internal environment in the body, known as homeostasis. It serves as a barrier that regulates which substances enter the body. The research team looked at which #genes were active in #immune and #epithelial cells from the children's nasal mucosa. They analyzed the cell samples once at the beginning and after the triple therapy and compared them with samples from the nasal mucosa of healthy children. They used single-cell transcriptomics, which allowed them to measure the activity of thousands of genes simultaneously. According to Trump and her colleagues, further studies are now needed that include CF patients of different ages and with different stages of lung disease. Among other things, the researchers want to determine whether the triple therapy also has a positive effect on the cells of the upper airways in older patients with more severe lung disease. #DZL, #DZG, #LungResearch, #LungDisease, #Science, #TripleTherapy, #CFTR, #CysticFibrosis, #Inflammation

Breaking the vicious cycle: Triple therapy strengthens nasal mucosal barrier function

Breaking the vicious cycle: Triple therapy strengthens nasal mucosal barrier function

https://dzl.de/en/

To view or add a comment, sign in

Explore topics